Cardio drug maker Portola Pharmaceuticals takes $60M extension
San Francisco-based drug company Portola Pharmaceuticals has taken a $60 million extension to its third round of funding to see it through Phase II trials for betrixaban, a drug intended to prevent blood clots.
The company is also working on an antiplatelet agent called PRT060128. If its drugs do well in trials, the company will likely head to an IPO, as we reported alongside its last $70 million fundung.
Managing Application Performance by Understanding Applications Learn more,… Continue Reading
Life sciences briefing: Tuesday, Jan. 8, 2008
TODAY’S HEADLINES:
CyberHeart pumps in $9M for cardiac-arrhythmia treatment (release)
Incubator ForSight launches third device company with $6M funding (release)
Primera Biosystems raises $21M for molecular diagnostics (release)
Biogen Idec, PDL BioPharma take stakes in Ophthotech (release)
Technitrol acquires medical-device component maker Sonion for $385M (release)
DLJ Merchant Banking takes control of dentristy-product maker Den-Mat (release)
SV Life Sciences appoints Hamish Cameron as venture partner (release)
CyberHeart pumps in $9M for cardiac-arrhythmia treatment – CyberHeart, a Menlo Park, Calif., startup developing a non-invasive treatment… Continue Reading
Life sciences briefing: Thursday, Dec. 13, 2007
TODAY’S HEADLINES:
Fovea Pharma sees €30M for eye drugs (release)
Ascendis Pharma raises €18M for time-release drugs (PDF release)
Arcion draws $9M for topical pain drugs (VentureWire, sub req’d)
Saladax Biomedical raises $8M for chemotherapy diagnostics (VW)
MedAssets prices IPO at top of range, raises up to $221M (IPO Home)
Pequot spin-off Longitude seeks $250M for life-science investments (VW)
Third Rock Ventures adds three new partners (release)
Ultrasound surgical co. ProRhythm files for bankruptcy protection (release)
The Hartford Financial Services Group acquires healthcare-benefit administrator… Continue Reading
Cardiovascular biotech Portola Pharmaceuticals raises $70M, eyes IPO
Portola Pharmaceuticals, a South San Francisco, Calif., biotech aiming to develop treatments for blood clots and other heart-related problems, raised $70 million in a third round of financing dominated by late-stage and public-market investors.
Among new investors in the round were Brookside Capital; AllianceBernstein; Teachers’ Private Capital, the private investment arm of Ontario Teachers’ Pension Plan; Goldman Sachs, T. Rowe Price, IBTM and CIDC. They were joined by existing investors Abingworth, Alta Partners, Advanced Technology Ventures,… Continue Reading
Portola Pharma gets $20M debt financing
Portola Pharmaceuticals, a South San Francisco biotech company developing cardiovascular and vascular disease therapies, has raised $20 million in debt financing from Hercules Technology Growth Capital.
Portola is already backed by venture firms Abingworth, Alta Partners, ATV, Frazier Healthcare Ventures, MPM Capital, Prospect Ventures and Sutter Hill Ventures.
The company said it has two drug candidates in clinical development: 1) an oral Factor Xa inhibitor in a Phase II trial for the prevention of Deep Vein Thrombosis… Continue Reading